{"id":39828,"date":"2025-10-06T19:16:15","date_gmt":"2025-10-06T13:46:15","guid":{"rendered":"https:\/\/edunovations.com\/currentaffairs\/?p=39828"},"modified":"2025-10-06T19:16:24","modified_gmt":"2025-10-06T13:46:24","slug":"lecanemab-leqembi","status":"publish","type":"post","link":"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/","title":{"rendered":"Lecanemab (Leqembi) Early-Stage Alzheimer\u2019s Drug Approval in Australia \u2013 Key Updates"},"content":{"rendered":"\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_84 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Lecanemab_Leqembi_approved_in_Australia_for_early-stage_Alzheimers_treatment_Learn_about_eligibility_side_effects_monitoring_and_implications_for_patients_and_healthcare\" >Lecanemab (Leqembi) approved in Australia for early-stage Alzheimer\u2019s treatment. Learn about eligibility, side effects, monitoring, and implications for patients and healthcare.<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#What_Is_Lecanemab_Leqembi\" >What Is Lecanemab (Leqembi)?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Approval_Process_and_Criteria\" >Approval Process and Criteria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Monitoring_and_Safety_Considerations\" >Monitoring and Safety Considerations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Implications_for_Alzheimers_Treatment_in_Australia\" >Implications for Alzheimer&#8217;s Treatment in Australia<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Why_This_News_Is_Important\" >Why This News Is Important<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Advancement_in_Alzheimers_Treatment\" >Advancement in Alzheimer&#8217;s Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Impact_on_Patients_and_Families\" >Impact on Patients and Families<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Economic_and_Healthcare_Considerations\" >Economic and Healthcare Considerations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Scientific_and_Medical_Community_Response\" >Scientific and Medical Community Response<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Future_Directions_in_Alzheimers_Research\" >Future Directions in Alzheimer&#8217;s Research<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Historical_Context\" >Historical Context<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Early_Alzheimers_Treatments\" >Early Alzheimer&#8217;s Treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Development_and_Approval_of_Leqembi\" >Development and Approval of Leqembi<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Global_Perspectives_on_Alzheimers_Treatment\" >Global Perspectives on Alzheimer&#8217;s Treatment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Key_Takeaways_from_%E2%80%9CAustralia_Approves_Lecanemab_for_Early-Stage_Alzheimers_Treatment%E2%80%9D\" >Key Takeaways from &#8220;Australia Approves Lecanemab for Early-Stage Alzheimer&#8217;s Treatment&#8221;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#FAQs_Frequently_Asked_Questions\" >FAQs: Frequently Asked Questions<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/lecanemab-leqembi\/#Some_Important_Current_Affairs_Links\" >Some Important Current Affairs Links<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Lecanemab_Leqembi_approved_in_Australia_for_early-stage_Alzheimers_treatment_Learn_about_eligibility_side_effects_monitoring_and_implications_for_patients_and_healthcare\"><\/span>Lecanemab (Leqembi) approved in Australia for early-stage Alzheimer\u2019s treatment. Learn about eligibility, side effects, monitoring, and implications for patients and healthcare.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Australia Approves Lecanemab (Leqembi) for Early-Stage Alzheimer&#8217;s Treatment<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a significant advancement for Alzheimer&#8217;s disease management, Australia&#8217;s Therapeutic Goods Administration (TGA) has approved lecanemab, marketed as Leqembi, for the treatment of early-stage Alzheimer&#8217;s disease. This decision marks a pivotal moment in dementia care, offering new hope to patients and families affected by this condition.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Lecanemab_Leqembi\"><\/span>What Is Lecanemab (Leqembi)?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Lecanemab is a monoclonal antibody developed by Eisai and Biogen, designed to target and reduce amyloid plaques in the brain\u2014a hallmark of Alzheimer&#8217;s disease. Administered via intravenous infusion every two weeks, Leqembi has demonstrated the ability to slow cognitive decline in individuals with mild cognitive impairment and mild dementia due to Alzheimer&#8217;s. However, it is not a cure and is intended for early-stage patients who are non-carriers or heterozygotes of the apolipoprotein E \u03b54 (ApoE \u03b54) gene variant.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Approval_Process_and_Criteria\"><\/span>Approval Process and Criteria<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Initially rejected by the TGA in October 2024 due to safety concerns, particularly regarding brain swelling and bleeding in patients carrying the ApoE \u03b54 gene, lecanemab&#8217;s approval was reconsidered following additional data submissions and discussions with the manufacturer. The TGA&#8217;s revised decision allows its use in patients without two copies of the ApoE \u03b54 gene, provided they meet specific diagnostic criteria. <\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Monitoring_and_Safety_Considerations\"><\/span>Monitoring and Safety Considerations<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Patients receiving Leqembi must undergo regular MRI scans to monitor for amyloid-related imaging abnormalities (ARIA), including brain swelling and microhemorrhages. While these side effects are relatively rare, they can be more prevalent in individuals with the ApoE \u03b54 gene, underscoring the importance of personalized treatment plans and vigilant monitoring. <\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Implications_for_Alzheimers_Treatment_in_Australia\"><\/span>Implications for Alzheimer&#8217;s Treatment in Australia<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The approval of Leqembi, alongside the earlier approval of Kisunla (donanemab), represents a significant step forward in the treatment of early-stage Alzheimer&#8217;s disease in Australia. These therapies offer patients the potential to slow disease progression, thereby extending quality of life. However, access remains a challenge due to high treatment costs and the need for inclusion in the Pharmaceutical Benefits Scheme (PBS) to reduce financial barriers. <\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\" id=\"Lecanemab-(Leqembi)\"><img decoding=\"async\" src=\"https:\/\/encrypted-tbn0.gstatic.com\/images?q=tbn:ANd9GcTvKBaTo0g1rItk9wExlrNZOgs8w29vmN6XqQ&amp;s\" alt=\"Lecanemab (Leqembi)\" style=\"width:573px;height:auto\" title=\"Lecanemab (Leqembi)\"\/><figcaption class=\"wp-element-caption\">Lecanemab (Leqembi)<\/figcaption><\/figure>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_News_Is_Important\"><\/span>Why This News Is Important<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Advancement_in_Alzheimers_Treatment\"><\/span>Advancement in Alzheimer&#8217;s Treatment<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The approval of Leqembi introduces a new therapeutic option for patients in the early stages of Alzheimer&#8217;s disease, addressing an unmet need in dementia care. By targeting the underlying pathology of the disease, Leqembi offers a disease-modifying approach rather than merely alleviating symptoms.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Impact_on_Patients_and_Families\"><\/span>Impact on Patients and Families<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">For individuals diagnosed with early-stage Alzheimer&#8217;s, Leqembi provides a potential to slow cognitive decline, thereby preserving independence and quality of life for a longer period. This development brings renewed hope to patients and their families, who have long awaited effective treatment options.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Economic_and_Healthcare_Considerations\"><\/span>Economic and Healthcare Considerations<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The high cost of Leqembi poses challenges for widespread accessibility. Without inclusion in the PBS, many patients may find the treatment financially prohibitive. Advocacy for government support and insurance coverage is crucial to ensure equitable access to this promising therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Scientific_and_Medical_Community_Response\"><\/span>Scientific and Medical Community Response<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The medical community has largely welcomed the approval of Leqembi, emphasizing the importance of early diagnosis and intervention in Alzheimer&#8217;s disease. Healthcare professionals stress the need for comprehensive patient monitoring and informed decision-making regarding treatment options.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Directions_in_Alzheimers_Research\"><\/span>Future Directions in Alzheimer&#8217;s Research<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The approval of Leqembi and Kisunla signals a shift towards disease-modifying therapies in Alzheimer&#8217;s treatment. Ongoing research into amyloid-targeting drugs and other innovative approaches holds promise for further advancements in the management of Alzheimer&#8217;s disease.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Historical_Context\"><\/span>Historical Context<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Early_Alzheimers_Treatments\"><\/span>Early Alzheimer&#8217;s Treatments<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Historically, Alzheimer&#8217;s disease treatments have focused on symptom management, with limited efficacy in altering disease progression. The introduction of disease-modifying therapies like Leqembi represents a paradigm shift in Alzheimer&#8217;s care.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Development_and_Approval_of_Leqembi\"><\/span>Development and Approval of Leqembi<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Leqembi underwent rigorous clinical trials, demonstrating its ability to reduce amyloid plaques and slow cognitive decline in early-stage Alzheimer&#8217;s patients. Following initial regulatory challenges, additional data and discussions led to its approval in Australia, reflecting a commitment to advancing dementia care.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Global_Perspectives_on_Alzheimers_Treatment\"><\/span>Global Perspectives on Alzheimer&#8217;s Treatment<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The approval of Leqembi aligns with global trends towards developing and implementing disease-modifying therapies for Alzheimer&#8217;s disease. International collaborations and research initiatives continue to drive progress in understanding and treating this complex condition.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Takeaways_from_%E2%80%9CAustralia_Approves_Lecanemab_for_Early-Stage_Alzheimers_Treatment%E2%80%9D\"><\/span>Key Takeaways from &#8220;Australia Approves Lecanemab for Early-Stage Alzheimer&#8217;s Treatment&#8221;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>S.No<\/th><th>Key Takeaway<\/th><\/tr><\/thead><tbody><tr><td>1<\/td><td><strong>Lecanemab (Leqembi) approved in Australia<\/strong>: The TGA has approved Leqembi for treating early-stage Alzheimer&#8217;s disease in specific patient populations. <\/td><\/tr><tr><td>2<\/td><td><strong>Targeted therapy for amyloid plaques<\/strong>: Leqembi works by targeting and reducing amyloid plaques in the brain, aiming to slow disease progression. <\/td><\/tr><tr><td>3<\/td><td><strong>Eligibility criteria<\/strong>: Suitable for patients without two copies of the ApoE \u03b54 gene variant and confirmed amyloid presence. <\/td><\/tr><tr><td>4<\/td><td><strong>Monitoring requirements<\/strong>: Patients must undergo regular MRI scans to monitor for potential side effects like brain swelling or bleeding. <\/td><\/tr><tr><td>5<\/td><td><strong>Advocacy for PBS inclusion<\/strong>: Efforts are ongoing to include Leqembi in the Pharmaceutical Benefits Scheme to improve accessibility and affordability.<\/td><\/tr><\/tbody><\/table><figcaption class=\"wp-element-caption\">Lecanemab (Leqembi)<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs_Frequently_Asked_Questions\"><\/span>FAQs: Frequently Asked Questions<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>1. What is Lecanemab (Leqembi)?<\/strong><br>Lecanemab, marketed as Leqembi, is a monoclonal antibody drug approved in Australia for early-stage Alzheimer&#8217;s disease. It targets and reduces amyloid plaques in the brain, helping slow cognitive decline in affected patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>2. Who is eligible to take Leqembi in Australia?<\/strong><br>Leqembi is approved for patients with early-stage Alzheimer&#8217;s who do not carry two copies of the ApoE \u03b54 gene variant. Patients must also have confirmed amyloid plaques in the brain.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>3. How is Leqembi administered?<\/strong><br>The drug is given via intravenous infusion every two weeks under medical supervision, with ongoing monitoring for safety.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>4. What are the major side effects of Leqembi?<\/strong><br>Patients may experience amyloid-related imaging abnormalities (ARIA), including brain swelling and microbleeds. These risks are higher in patients carrying the ApoE \u03b54 gene.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>5. Why was Leqembi initially rejected by the TGA?<\/strong><br>The Therapeutic Goods Administration (TGA) initially rejected Leqembi due to safety concerns related to brain swelling and bleeding in patients with the ApoE \u03b54 gene. Approval was granted after additional clinical data and discussions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>6. How does Leqembi impact Alzheimer\u2019s disease treatment?<\/strong><br>Unlike traditional symptom-managing drugs, Leqembi is a disease-modifying therapy. It slows the progression of early-stage Alzheimer&#8217;s by targeting amyloid plaques, improving patient quality of life.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>7. Are there any cost considerations for patients?<\/strong><br>Leqembi is expensive, and access may be limited unless it is included in Australia\u2019s Pharmaceutical Benefits Scheme (PBS). Advocacy for PBS inclusion is ongoing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>8. What other Alzheimer\u2019s drugs are available in Australia?<\/strong><br>Another recently approved drug is Donanemab (marketed as Kisunla), which also targets amyloid plaques and slows cognitive decline in early-stage Alzheimer&#8217;s patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Some_Important_Current_Affairs_Links\"><\/span>Some Important Current Affairs Links<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/national\/\" target=\"_blank\" rel=\"noreferrer noopener\">State Current Affairs<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-outline is-style-outline--2\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/sports\/\" target=\"_blank\" rel=\"noreferrer noopener\">Sports Current Affairs<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-outline is-style-outline--3\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/international\/\" target=\"_blank\" rel=\"noreferrer noopener\">International Current Affairs<\/a><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/banking\/\" target=\"_blank\" rel=\"noreferrer noopener\">Banking Current Affairs<\/a><\/div>\n\n\n\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/railway\/\" target=\"_blank\" rel=\"noreferrer noopener\">Railways Current Affairs<\/a><\/div>\n\n\n\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/defence\/\" target=\"_blank\" rel=\"noreferrer noopener\">Defence Current Affairs<\/a><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--4\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs?newsmaticargs=custom&amp;posts=today\" target=\"_blank\" rel=\"noreferrer noopener\">Daily Current Affairs<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-outline is-style-outline--5\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairsinhindi\/\" target=\"_blank\" rel=\"noreferrer noopener\">Current Affairs In Hindi<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-outline is-style-outline--6\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/news-and-notifications\/\" target=\"_blank\" rel=\"noreferrer noopener\">News and Notifications<\/a><\/div>\n<\/div>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.edunovations.quiz\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" width=\"900\" height=\"150\" src=\"https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/03\/Banner-current-affairs-2-1.jpg\" alt=\"Download this App for Daily Current Affairs MCQ&#039;s\" class=\"wp-image-247\" title=\"\" srcset=\"https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/03\/Banner-current-affairs-2-1.jpg 900w, https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/03\/Banner-current-affairs-2-1-300x50.jpg 300w, https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/03\/Banner-current-affairs-2-1-768x128.jpg 768w\" sizes=\"(max-width: 900px) 100vw, 900px\" \/><\/a><figcaption class=\"wp-element-caption\">Download this App for Daily Current Affairs MCQ&#8217;s<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\" id=\"News-Website-Development-Company\"><a href=\"https:\/\/www.martindiainfotech.com\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" width=\"900\" height=\"150\" src=\"https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/04\/News-Website-Development-Company-Banner.png\" alt=\"News Website Development Company\" class=\"wp-image-438\" title=\"News Website Development Company\" srcset=\"https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/04\/News-Website-Development-Company-Banner.png 900w, https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/04\/News-Website-Development-Company-Banner-300x50.png 300w, https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/04\/News-Website-Development-Company-Banner-768x128.png 768w\" sizes=\"(max-width: 900px) 100vw, 900px\" \/><\/a><figcaption class=\"wp-element-caption\">News Website Development Company<\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Lecanemab (Leqembi) approved in Australia for early-stage Alzheimer\u2019s treatment. Learn about eligibility, side effects, monitoring, and implications for patients and healthcare. Australia Approves Lecanemab (Leqembi) for Early-Stage Alzheimer&#8217;s Treatment In a significant advancement for Alzheimer&#8217;s disease management, Australia&#8217;s Therapeutic Goods Administration (TGA) has approved lecanemab, marketed as Leqembi, for the treatment of early-stage Alzheimer&#8217;s disease&#8230;.<\/p>\n","protected":false},"author":6,"featured_media":39858,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,153],"tags":[28729,28731,28726,28730,28727,28733,28728],"class_list":["post-39828","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-international","category-miscellaneous","tag-alzheimers-treatment","tag-cognitive-decline","tag-disease-modifying-therapy","tag-early-stage-dementia","tag-lecanemab","tag-leqembi","tag-tga-approval"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/posts\/39828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/comments?post=39828"}],"version-history":[{"count":3,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/posts\/39828\/revisions"}],"predecessor-version":[{"id":39859,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/posts\/39828\/revisions\/39859"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/media\/39858"}],"wp:attachment":[{"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/media?parent=39828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/categories?post=39828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/tags?post=39828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}